Provided by Tiger Fintech (Singapore) Pte. Ltd.

Rhythm Pharmaceuticals Inc.

61.74
+0.40000.65%
Post-market: 61.740.00000.00%19:05 EDT
Volume:628.86K
Turnover:38.70M
Market Cap:3.90B
PE:-14.23
High:61.96
Open:61.11
Low:60.93
Close:61.34
Loading ...

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
26 Feb

Rhythm Pharmaceuticals Q4 Loss Widens, Revenue Increases

MT Newswires Live
·
26 Feb

Rhythm Pharmaceuticals Inc - Cash Runway Extended Into 2027

THOMSON REUTERS
·
26 Feb

Earnings Flash (RYTM) Rhythm Pharmaceuticals Posts Q4 Net Loss $0.72 a Share, vs. FactSet Est of $0.69 Loss

MT Newswires Live
·
26 Feb

Rhythm Pharmaceuticals Q4 EPS $(0.72), Inline, Sales $41.83M Beat $38.48M Estimate

Benzinga
·
26 Feb

BRIEF-Rhythm Pharmaceuticals Q4 Net Income USD -43.294 Million

Reuters
·
26 Feb

Rhythm Pharmaceuticals Inc - Q4 Shr Loss $0.72

THOMSON REUTERS
·
26 Feb

Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update

GlobeNewswire
·
26 Feb

Rhythm Pharmaceuticals Price Target Maintained With a $64.00/Share by Needham

Dow Jones
·
24 Feb

Rhythm Pharmaceuticals Price Target Maintained With a $64.00/Share by Needham

Dow Jones
·
19 Feb

Rhythm Pharmaceuticals to Present at Oppenheimer Annual Healthcare Life Sciences Conference in February

GlobeNewswire
·
05 Feb

Exploring High Growth Tech Stocks in January 2025

Simply Wall St.
·
23 Jan

Rhythm Pharmaceuticals (RYTM) Soars 5.5%: Is Further Upside Left in the Stock?

Zacks
·
22 Jan

Subdued Growth No Barrier To Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Price

Simply Wall St.
·
19 Jan

Rhythm Pharmaceuticals price target raised to $60 from $58 at BofA

TIPRANKS
·
12 Jan

Analysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (AMGN), Rhythm Pharmaceuticals (RYTM) and Lyell Immunopharma (LYEL)

TIPRANKS
·
11 Jan

TD Cowen Keeps Their Buy Rating on Rhythm Pharmaceuticals (RYTM)

TIPRANKS
·
11 Jan

BRIEF-Rhythm Pharmaceuticals Imcivree Net Revenue FY24 Expected To Be About $130 Million

Reuters
·
10 Jan

Rhythm Pharmaceuticals Inc: Net REV FY24 Expected to Be About $130 Mln

THOMSON REUTERS
·
10 Jan

Rhythm Pharmaceuticals:on Track to Report Topline Data From Global Phase 3 Trial Evaluating Setmelanotide in Acquired Hypothalamic Obesity in H1 2025

THOMSON REUTERS
·
10 Jan